Frederike K. Engels

891 total citations
17 papers, 681 citations indexed

About

Frederike K. Engels is a scholar working on Oncology, Pharmacology and Pharmacology. According to data from OpenAlex, Frederike K. Engels has authored 17 papers receiving a total of 681 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 5 papers in Pharmacology and 4 papers in Pharmacology. Recurrent topics in Frederike K. Engels's work include Cancer Treatment and Pharmacology (8 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Cannabis and Cannabinoid Research (3 papers). Frederike K. Engels is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Cannabis and Cannabinoid Research (3 papers). Frederike K. Engels collaborates with scholars based in Netherlands, United States and Sweden. Frederike K. Engels's co-authors include Jaap Verweij, Ron A. A. Mathôt, Walter J. Loos, Ron H.J. Mathijssen, Peter de Bruijn, Alex Sparreboom, Ron H. N. van Schaik, Floris A. de Jong, Erik A.C. Wiemer and Jessica M. van der Bol and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and European Journal of Cancer.

In The Last Decade

Frederike K. Engels

17 papers receiving 656 citations

Peers

Countries citing papers authored by Frederike K. Engels

Since Specialization

Citations

This map shows the geographic impact of Frederike K. Engels's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frederike K. Engels with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frederike K. Engels more than expected).

Fields of papers citing papers by Frederike K. Engels

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frederike K. Engels. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frederike K. Engels. The network helps show where Frederike K. Engels may publish in the future.

Co-authorship network of co-authors of Frederike K. Engels

This figure shows the co-authorship network connecting the top 25 collaborators of Frederike K. Engels. A scholar is included among the top collaborators of Frederike K. Engels based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frederike K. Engels. Frederike K. Engels is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group 2022 ·The Lancet Child & Adolescent Health ·Esmée C. de Baat, Elvira C van Dalen, Renée L. Mulder, Melissa M. Hudson, Matthew J. Ehrhardt, Frederike K. Engels, Elizabeth A. M. Feijen, Heynric B. Grotenhuis, Jan M. Leerink, Livia Kapusta, Gertjan J.L. Kaspers, Remy Merkx, Luc Mertens, Roderick Skinner, Wim J. E. Tissing, Florent de Vathaire, Paul C. Nathan, Leontien C.M. Kremer, Annelies M. C. Mavinkurve‐Groothuis, Saro H. Armenian	39
2	Therapeutic Drug Monitoring of Methotrexate in Plasma Using Ultra High-Performance Liquid Chromatography–Electrospray Ionization–Tandem Mass Spectrometry: Necessary After Administration of Glucarpidase in Methotrexate Intoxications 2018 ·Therapeutic Drug Monitoring ·(unknown), (unknown), Frederike K. Engels, Inge M. van der Sluis, Birgit C. P. Koch	12
3	Drug-drug interactions in pediatric oncology patients 2017 ·Pediatric Blood & Cancer ·(unknown), (unknown), Teun van Gelder, (unknown), Inge M. van der Sluis, Roelof W. F. van Leeuwen, Frederike K. Engels	17
4	CYP3A422* Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity 2013 ·Clinical Cancer Research ·Anne‐Joy M. de Graan, Laure Elens, Jason A. Sprowl, Alex Sparreboom, Lena E. Friberg, Bronno van der Holt, Pleun J. de Raaf, Peter de Bruijn, Frederike K. Engels, Ferry A.L.M. Eskens, Erik A.C. Wiemer, Jaap Verweij, Ron H.J. Mathijssen, Ron H. N. van Schaik	91
5	Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study 2011 ·Clinical Cancer Research ·Frederike K. Engels, Walter J. Loos, Jessica M. van der Bol, Peter de Bruijn, Ron H.J. Mathijssen, Jaap Verweij, Ron A. A. Mathôt	63
6	Application of prolonged microdialysis sampling in carboplatin-treated cancer patients 2008 ·Cancer Chemotherapy and Pharmacology ·Inge R. Konings, Frederike K. Engels, Stefan Sleijfer, Jaap Verweij, Erik A.C. Wiemer, Walter J. Loos	14
7	Influence of ketoconazole on the fecal and urinary disposition of docetaxel 2007 ·Cancer Chemotherapy and Pharmacology ·Frederike K. Engels, Walter J. Loos, Ron A. A. Mathôt, Ron H. N. van Schaik, Jaap Verweij	7
8	Medicinal cannabis in oncology 2007 ·European Journal of Cancer ·Frederike K. Engels, Floris A. de Jong, Ron H.J. Mathijssen, Joëlle A. Erkens, Ron M. C. Herings, Jaap Verweij	24
9	Pitfalls of the application of microdialysis in clinical oncology: Controversial findings with docetaxel 2007 ·Journal of Pharmaceutical and Biomedical Analysis ·Walter J. Loos, William C. Zamboni, Frederike K. Engels, Peter de Bruijn, (unknown), Ronald de Wit, Jaap Verweij, Erik A.C. Wiemer	14
10	Medicinal Cannabis Does Not Influence the Clinical Pharmacokinetics of Irinotecan and Docetaxel 2007 ·The Oncologist ·Frederike K. Engels, Floris A. de Jong, Alex Sparreboom, Ron A. A. Mathôt, Walter J. Loos, Jos Kitzen, Peter de Bruijn, Jaap Verweij, Ron H.J. Mathijssen	65
11	Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel 2006 ·Cancer Biology & Therapy ·Frederike K. Engels, Ron A. A. Mathôt, Walter J. Loos, Ron H. N. van Schaik, Jaap Verweij	37
12	Alternative drug formulations of docetaxel: a review 2006 ·Anti-Cancer Drugs ·Frederike K. Engels, Ron A. A. Mathôt, Jaap Verweij	173
13	Pharmacokinetic Optimization of Docetaxel Dosing 2006 ·Data Archiving and Networked Services (DANS) ·Frederike K. Engels	2
14	Docetaxel administration schedule: From fever to tears? A review of randomised studies 2005 ·European Journal of Cancer ·Frederike K. Engels, Jaap Verweij	75
15	Quantification of [3H]docetaxel in feces and urine: development and validation of a combustion method 2005 ·Anti-Cancer Drugs ·Frederike K. Engels, (unknown), Walter J. Loos, Jaap Verweij, Willem H. Bakker, Eric P. Krenning	3
16	Medicinal Cannabis in Oncology Practice: Still a Bridge Too Far? 2005 ·Journal of Clinical Oncology ·Floris A. de Jong, Frederike K. Engels, Ron H.J. Mathijssen, Lia van Zuylen, Jaap Verweij, Remco P. H. Peters, Alex Sparreboom	16
17	Neuropsychiatric side effects of interferon-alfa therapy. 2003 ·Pharmacy World & Science ·Arthur R. Van Gool, Wim H.J. Kruit, Frederike K. Engels, G. Stoter, (unknown)	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact